To assess the efficacy of ABBV-400 in each solid tumor indication, including advanced or metastatic hepatocellular (HCC), biliary tract cancer (BTC), pancreatic ductal adenocarcinoma (PDAC), esophageal squamous cell carcinoma (ESCC), triple negative (TN) breast cancer (BC), hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) BC, and head and neck squamous cell carcinoma (HNSCC). The purpose of this study is to evaluate ABBV-400 in subjects with select solid tumors. This study will consist of multiple cohorts with each cohort investigating ABBV-400 at 3 mg/kg Q3W.
Principal Investigator
Daruka Mahadevan
Regulatory Point of Contact
Frances Crawford
210-450-5037
crawfordf1@uthscsa.edu
Regulatory Point of Contact
Myrna Montenegro
210-450-5954
montenegro@uthscsa.edu
Regulatory Point of Contact
Kathleen Rodriguez
210-450-1365
rodriguezk3@uthscsa.edu
Regulatory Point of Contact
Benjamin Schleif
210-450-1366
schleifb@uthscsa.edu
Regulatory Point of Contact
Morgan Seekatz
210-450-1133
seekatz@uthscsa.edu